Werewolf Therapeutics to Participate in Upcoming Investor Conferences
Rhea-AI Summary
Werewolf Therapeutics (NASDAQ: HOWL), a biopharmaceutical company focused on developing conditionally activated therapeutics for cancer and immune-mediated conditions, has announced its participation in two major investor conferences in May 2025:
- The Citizens Life Sciences Conference on May 8, 2025, at 10:00am ET in New York Hilton Midtown
- The Bank of America Securities 2025 Health Care Conference on May 14, 2025, at 3:15pm PT at The Encore Hotel, Las Vegas
Management will participate in fireside chats at both events. Webcasts will be available on the company's investor relations website, with replays accessible for approximately 90 days after the conferences.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, HOWL gained 4.84%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
WATERTOWN, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions, today announced that management will participate in the following upcoming investor conferences in the month of May:
The Citizens Life Sciences Conference 2025
Date: Thursday, May 8, 2025
Time: 10:00am ET
Location: New York Hilton Midtown
Management will participate in a fireside chat
Bank of America Securities 2025 Health Care Conference
Date: Wednesday, May 14, 2025
Time: 3:15pm PT
Location: The Encore Hotel, Las Vegas, NV
Management will participate in a fireside chat
Live webcast links for the fireside chats will be available at https://investors.werewolftx.com/news-and-events/events. Archived replays will be available for approximately 90 days following the respective conferences.
About Werewolf Therapeutics:
Werewolf Therapeutics, Inc., is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions. The Company is leveraging its proprietary PREDATOR® platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Werewolf’s INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. The Company’s most advanced clinical stage product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and Interleukin-12 (IL-12) INDUKINE molecules, respectively, for the treatment of solid tumors. Werewolf is advancing WTX-124 in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor and WTX-330 in multiple tumor types or Non-Hodgkin Lymphoma as a single agent. To learn more visit www.werewolftx.com.
WEREWOLF®, the WEREWOLF logo, PREDATOR®, INDUKINE™ and other Werewolf trademarks, service marks, graphics and logos are trade names, trademarks or registered trademarks of Werewolf Therapeutics, Inc., in the United States or other countries. All rights reserved.
Investor Contact
Dan Ferry
LifeSci Advisors
617.430.7576
daniel@lifesciadvisors.com
Media Contact:
Amanda Sellers
Deerfield Group
301.332.5574
amanda.sellers@deerfieldgroup.com
Company Contact:
Timothy Trost
Chief Financial Officer
Werewolf Therapeutics
ttrost@werewolftx.com
FAQ
When is Werewolf Therapeutics (HOWL) presenting at the Citizens Life Sciences Conference 2025?
What time is Werewolf Therapeutics (HOWL) presenting at the Bank of America Securities Healthcare Conference 2025?
Where can I watch Werewolf Therapeutics (HOWL) investor conference presentations?
What type of company is Werewolf Therapeutics (HOWL)?
